Abzena Expands ADC Capabilities
Abzena has completed the facility remodeling for its new antibody-drug conjugate (ADC) GMP manufacturing suite at its Bristol, PA site.
The facility is being equipped with state-of-the-art Sartorius and GE equipment for single use scale-up, manufacture and purification processes. The environmentally controlled suite will enable Abzena to produce ADCs for preclinical and early phase clinical studies. The suite is a significant part of Abzena's integrated ADC capabilities for the design, development and manufacture of ADCs.
The facility and equipment verification and qualification for this ADC GMP manufacturing suite is currently underway, and scheduled for completion around the end of the second quarter of 2018.
Completion of the GMP ADC manufacturing suite construction marks a key point in Abzena's program to expand the group's integrated ADC chemistry solutions. This ADC manufacturing suite complements the existing GMP manufacturing capability for the scale-up and manufacture of highly potent payload-linker constructs, and the upgrading and expansion of Abzena's biologics process development and manufacturing capabilities in San Diego. The plans are on track for the initial relocation for Abzena's biologics manufacturing process and analytical development groups into the new San Diego facility during April 2018.
Abzena has existing client process development programs scheduled for the Bristol ADC manufacturing facility including an ADC utilizing the group's proprietary ThioBridge conjugation technology and another that has benefitted from an integrated program comprising cell line development, antibody production and development and manufacture of the ADC product including the linker-payload reagent.
"The completion of this facility is a significant step in realizing Abzena's vision of being a full service and technology provider for the design, development and manufacture of ADCs," said Sanjeevani Ghone, vice president and site head, Abzena, Bristol PA. "Our recent contracts are a testament to our client's confidence in our expertise and experience in this field."
Looking for chemical products? Let suppliers reach out to you!
Syngene Signs R&D Agreement with GSK
2026-06-14
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
West Asia Tensions Squeeze Pharma Raw Materials
-
Novo Nordisk Signs $812 Million Deal with Deep Apple for New Obesity Drugs
-
India Dismisses Patent Infringement Claims Assures Commitment to IP Rights
-
Study Finds Obesity Injections Lose Effectiveness Real World Weight Loss Drops to 8.7 Percent
-
Indian Pharma Market Grows 7.2% in May GSK’s Augmentin Slips to 12th
-
Merck’s Enlicitide Decanoate Achieves Key Breakthrough in Cholesterol Trials
-
Pfizer and US Government Discuss Drug Prices No Firm Commitments Yet
-
Pfizer Seen Holding Strategic Edge in Bidding Battle for Metsera
-
Cipla CEO Calls Tirzepatide a High-Science Product with Strong Market Outlook
-
Novo Nordisk Enters High-Stakes Bidding War with Pfizer for Metsera
Recommend Reading
-
Canada Issues Non-Compliance Notice to Dr. Reddy’s on Semaglutide Generic
-
Strides Pharma Reports Strong Q2 as Net Profit Surges 82%
-
Pfizer Sues Metsera and Novo Nordisk Over Rival Obesity Drug Strategy
-
India Strengthens Drug Approval Oversight with Expanded CDSCO Powers
-
Merck and Eisai Halt Late-Stage Trial for Liver Cancer Therapy
-
Vita Group Achieves 56 Percent Emissions Reduction Celebrates 75 Years with Sustainability Milestones
-
In April, the Chinese phenol market continued to decline
-
Birla Opus Files Antitrust Complaint Against Asian Paints Market Showdown Likely
-
In April, China's gasoline and diesel market trends declined
-
Negative Factors Persist, Palm Oil Market Weakens and Declines